How do you pay?

How to pay the least

Ask for the cash price

Akeega

We didn’t find one.

  1. Ask your pharmacy for Akeega’s cash price, and one or two other pharmacies too.
  2. Akeega’s savings card works only with insurance from a job or one you bought.

Free from the maker, if you qualify Johnson & Johnson Patient Assistance Program. Patients’ income must be equal to or less than 300% of Federal Poverty Level (FPL). Or call 1-833-742-0791.

See if you qualify 

Compare every option

Question
Brand nameAkeega
Authorized genericniraparib tosylate and abiraterone
Regular genericniraparib tosylate and abiraterone
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Akeega?
The original
–
–

Brand nameThe maker’s card

J&J withMe Savings Program

Savings card from Johnson & Johnson

No insuranceNeeds insuranceNo cash price listed.
Insurance $0 a month

Sign up on jnjwithme.com 

Or call 1-833-565-9631.

In the maker’s words

“Eligible patients pay $0 per month.”

From the maker’s offer on jnjwithme.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Akeega itself, from the same company, sold without the brand name, and usually for less. For now Akeega is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

AKEEGA is a combination of niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with:

  • deleterious or suspected deleterious BRCA2-mutated ( BRCA2m) metastatic castration-sensitive prostate cancer (mCSPC).
  • deleterious or suspected deleterious BRCA-mutated ( BRCAm) metastatic castration-resistant prostate cancer (mCRPC).
  • Select patients for therapy based on an FDA-approved test for AKEEGA.

Source: the FDA label for Akeega (Janssen Biotech, Inc.), December 18, 2025. Full label on DailyMed 

Good to know